Precision Medicine Poised to Transform Severe Asthma Treatment in South Korea

SEOUL, south korea (April 29, 2025) – A shift toward precision medicine, utilizing detailed ⁤phenotype evaluations and biologic therapies, ⁢is expected⁤ to revolutionize the treatment of severe asthma, according ‍to experts. Current treatments primarily⁤ focus on managing symptoms, but a new paradigm emphasizing precise ⁢diagnosis and pathology-based treatment is⁤ needed, according to Kim Sang-heon, a professor of respiratory allergic medicine at Hanyang University Hospital.

Asthma: A Global health Concern

Asthma, a chronic respiratory disease affecting an estimated 340 million people ‍worldwide, impacts individuals across all age groups. in South Korea, it is estimated that 3% to 5% of the population suffers from asthma, experiencing ⁢symptoms such as coughing, shortness of breath, and wheezing.

The Challenge of Severe Asthma

A important concern arises when these symptoms remain poorly controlled or suddenly worsen ⁤despite conventional treatments. This is often the case for patients with severe asthma, representing approximately 5% of all asthma sufferers. According to Kim, the⁢ medical expenses associated with ⁤severe asthma patients account for roughly 50% of the⁤ total asthma-related healthcare costs. This underscores the critical need for early identification and systematic management of severe⁢ asthma as a national healthcare priority.

gaps in diagnosis and Treatment

Unlike typical asthma cases manageable in ⁢primary care settings, severe asthma necessitates a more‍ specialized approach. However, a lack of awareness in primary care and structural limitations hinder timely referrals to specialized hospitals, severe asthma centers, and ‍respiratory⁢ professionals, Kim said.

The Risks of ⁢Steroid Overuse

The overuse of oral steroids to manage asthma symptoms poses another ⁢challenge. While steroids offer rapid symptom relief, prolonged use can lead to chronic side effects, including⁣ osteoporosis, hypertension, and diabetes, Kim cautioned. This highlights the need for choice treatment strategies.

Biologic Therapies: A Potential Game-Changer

Biologic therapies are emerging as a promising solution to reduce steroid dependence and transition towards⁣ precision-based, personalized treatment for severe asthma patients.Some patients who have not responded to traditional treatments have experienced ⁤significant improvements with biologic formulations.

Access to Biologics:⁢ Challenges and Costs

While six biologic therapies are approved for use ⁣in South Korea, only a limited number are⁢ covered by insurance. Restrictive reimbursement criteria, such ⁣as requiring a peripheral blood eosinophil count exceeding ⁢300 cells/μl, asthma exacerbations in⁢ the past year, and at least four hospital visits, limit patient access. Kim⁤ noted that these conditions,such as requiring four emergency room visits annually or facing life-threatening situations,create barriers to access.

The cost of non-reimbursed biologic treatments can ⁤exceed 10 million won (approximately $7,600 USD) per year, depending on ⁢the specific medication,⁣ Kim said.

Precision Medicine Poised to Transform‍ Severe Asthma Treatment: Your Questions Answered

H2: What’s New in severe Asthma Treatment in South ‍Korea?

According to⁤ experts⁢ like Professor Kim Sang-heon,⁣ a shift towards ‍precision medicine is underway in South Korea, aiming to revolutionize severe asthma treatment.This new approach focuses on a more precise diagnosis⁤ and pathology-based ⁣treatment, moving away ⁢from simply managing symptoms.

H2: What is asthma, and How Common Is It?

Q: What is asthma?

Asthma is ⁢a chronic respiratory disease, meaning it’s⁤ a long-term condition affecting the airways.

Q: How⁤ many people worldwide are affected by asthma?

Approximately 340 million people worldwide live with asthma.

Q: How prevalent is asthma in South Korea?

In South Korea, an estimated 3% to ‍5% of the population suffers from asthma.

Q: what⁣ are the common symptoms of asthma?

Common asthma symptoms include:

Coughing

Shortness of breath

Wheezing

H2: Understanding Severe Asthma: The⁣ Challenges

Q: What is severe asthma?

Severe⁣ asthma is a condition where asthma symptoms ‍are poorly controlled or ⁣suddenly worsen despite ⁤standard treatments.

Q: Is severe asthma ⁣a large percentage of the cases?

severe asthma affects ⁣about ⁢5% of all asthma sufferers.

Q: How ⁤does severe asthma effect healthcare ⁤costs?

Patients with ⁢severe asthma account for roughly 50% of total asthma-related healthcare costs. this makes early identification and management of severe asthma a national healthcare priority.

H2: Why is Early Diagnosis and Management of Severe ⁢Asthma So Important?

Q: ‍What are⁣ the main⁤ challenges in diagnosing and treating severe asthma?

Unlike typical asthma cases, ⁣severe asthma needs a specialized approach. A lack of ‍awareness in primary care settings and structural⁣ limitations can hinder timely referrals to specialists.

H2: The Risks of Long-Term Steroid Use

Q: ⁣Why ‍are oral⁣ steroids a concern in treating severe asthma?

While oral steroids provide rapid relief from asthma symptoms, their prolonged use can lead to chronic ‍side effects, including:

⁢ Osteoporosis

Hypertension

Diabetes

H2: ‍Biologic Therapies: A Promising Solution

Q:⁢ What are biologic therapies?

Biologic therapies are ⁤medications that target specific parts of ⁢the ⁤immune system involved in asthma. They are emerging as a promising treatment option.

Q: how can biologic therapies help asthma patients?

Biologic therapies are designed to reduce steroid‍ dependence and⁣ allow for a more personalized treatment⁤ approach. Patients who haven’t responded to conventional treatments have seen meaningful improvements with⁤ biologics.

H2:⁤ Accessing Biologic Therapies in ⁤South Korea

Q: Are biologic therapies readily available in South Korea?

While six⁤ biologic therapies are approved in South korea, access ⁣is limited.

Q: What are the ‍barriers to accessing biologic therapies?

Restrictive reimbursement criteria are major barriers. For example,‍ in order to have access, one may need:

A peripheral blood eosinophil⁤ count exceeding 300 cells/μl

Experience asthma exacerbations ⁢in the past year

* ‍ Have at least four hospital visits

Q: What are the potential costs for⁤ these treatments?

The‍ cost of non-reimbursed biologic treatments can exceed⁢ 10 ⁤million won⁤ (approximately $7,600 USD) per year, ⁣depending on⁤ the medication.

H2: ‍Key Takeaways: Summarizing ⁣the Challenges and Opportunities

Q: What are the overall challenges and opportunities in ⁢treating severe asthma in South⁤ Korea?

| Feature ⁢ | Challenge ⁤ ‍ ‍ ‍ ‍ ⁤ ⁣ ‍⁢ ⁣ ⁢ | Opportunity ‍‍ ‍ ‍ ⁢ ⁣ ⁣ |

| ⁤————- | —————————————————————————– |‍ ————————————————————————— |

| Diagnosis | Lack ⁣of awareness and timely referrals in ⁢primary care. ⁣ ⁢ | Transition⁤ to ⁢precision medicine for accurate⁤ and⁢ timely diagnosis. ⁢ |

| Treatment ⁢ | Over-reliance on steroids and associated side effects. | Use of biologic therapies for personalized treatment to reduce steroid use. |

| Access ⁢ | Restrictive reimbursement criteria limit access to innovative⁣ therapies. ⁢ |⁤ Improve patient access to ⁣biologics and support ⁢affordability. |

| Cost ⁤ |⁢ High cost of non-reimbursed treatments. ⁣ ⁢ ⁢ ‍ ⁣ ⁤ | Potential for improved cost-effectiveness⁣ with optimized treatments. ⁢ ⁤ ⁤ |

|⁣ Overall⁢ goal | To provide⁣ systematic⁣ management‍ of severe asthma. ⁤ ⁢ ‍ ⁣⁤ | Revolutionizing severe asthma treatment using precision medicine. |